Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development

Journal of Ocular Pharmacology and Therapeutics

Volumn 32, Issue 3, 2016, Pages 135-144

  Bansal, Pooja ^a   Garg, Satpal ^b   Sharma, Yograj ^a   Venkatesh, Pradeep ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Vision Eye Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GANCICLOVIR; LIPOSOME; MICROSPHERE; NANOCARRIER; NANOMER; NANOSPHERE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

BIODEGRADABLE IMPLANT; CELL ENCAPSULATION; DRUG DELIVERY SYSTEM; EYE DISEASE; HUMAN; HYDROGEL; INTRAOCULAR IMPLANT; INTRAVITREAL IMPLANT; IONTOPHORESIS; LIPOSOMAL DELIVERY; MICROCATHETER; MICROELECTROMECHANICAL INTRAOCULAR DRUG DELIVERY; MICROELECTROMECHANICAL SYSTEM; NANOPHARMACEUTICS; NANOTECHNOLOGY; NON BIODEGRADABLE IMPLANT; OPHTHALMIC DRUG DELIVERY DEVICE; OPHTHALMOLOGICAL IMPLANT; PORT DELIVERY SYSTEM; POSTERIOR EYE SEGMENT; POSTERIOR EYE SEGMENT DISORDER; RENEXUS IMPLANT; REVIEW; SUPRACHOROIDAL DRUG DELIVERY; SUSTAINED DRUG RELEASE; THERMORESPONSIVE HYDROGEL; TRANSSCLERAL DRUG DELIVERY; ANIMAL; DEVICES; EYE DISEASES; PROCEDURES;

ANIMALS; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; POSTERIOR EYE SEGMENT;

EID: 84963812411     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2015.0133     Document Type: Review

References (78)

1. Bourlais, C.L., Acar, L., Zia, H., et al. Ophthalmic drug delivery systems-recent advances. Prog. Retin. Eye. Res. 17:33-58, 1998.
2. Patel, A., Kishore, C.K., Vibhuti, A.V., and Mitra, A.K. Ocular drug delivery systems: An overview. World J. Pharmacol. 2:47-64, 2013.
3. Geroski, D.H., and Edelhauser, H.F. Drug delivery for posterior segment eye diseases. Invest. Ophthalmol. Vis. Sci. 41:961-964, 2000.
4. Thrimawithana, T.R., Young, S., Bunt, C.R., Green, C., and Alany, R.G. Drug delivery to the posterior segment of the eye. Drug Discov. Today. 16:270-277, 2011.
5. Urtti, A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58:1131-1135, 2008.
6. Schoenwald, R.D. Ocular drug delivery-pharmacokinetic considerations. Clin. Pharmacokinet. 18:255-269, 1990.
7. Amo, E.M., and Urtti, A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today. 13:135-143, 2008.
8. Silva, G.R., Fialho, S.L., Siqueira, R.C., Jorge, R., and Jú-nior, A.S.C. Implants as drug delivery devices for the treatment of eye diseases. Braz. J. Pharm. Sci. 46:585-595, 2010.
9. Haghjou, N., Soheilian, M., and Abdekhodaie, M.J. Sustained release intraocular drug delivery devices for treatment of uveitis. J. Ophthalmic Vis. Res. 6:317-329, 2011.
10. Dhillon, B., Kamal, A., and Leen, C. Intravitreal sustainedrelease ganciclovir implantation to control cytomegalovirus retinitis in AIDS. Int. J. STD AIDS. 9:227-230, 1998.
11. Ashton, P., Brown, J.D., Pearson, P.A., et al. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J. Ocul. Pharmacol. 8:343-347, 1992.
12. Martin, D.F., Parks, D.J., Mellow, S.D., et al. Treatment of cytomegalovirus retinitis with an intraocular sustainedrelease ganciclovir implant: A randomized controlled clinical trial. Arch. Ophthal. 112:1531-1539, 1994.
13. Jabs, D.A., Ahuja, A., Natta, M.V., Dunn, J.P., and Yeh, S. Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 120:1262-1270, 2013.
14. Hazirolan, D., and Pleyer, U. Think global-act local: Intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthalmic Res. 49:59-65, 2013.
15. Falavarjani, K.G. Implantable posterior segment drug delivery devices-novel alternatives to currently available treatments. J. Ophthalmic Vis. Res. 4:191-193, 2009.
16. Callanan, D.G., Jaffe, G.J., Martin, D.F., et al. Treatment of posterior uveitiswith a fluocinolone actinide implant: Three-year clinical trial results. Arch. Ophthalmol. 126:1191-1201, 2008.
17. Jaffe, G.J., Martin, D., Callanan, D., et al. Fluocinolone actinide implant (Retisert) for noninfectious posterior uveitis: Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 113:1020-1027, 2006.
18. Pavesio, C., Zierhut, M., Bairi, K., Comstock, T.L., and Usner, D.W. Evaluation of an intravitreal fluocinolone actinide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 117:567-575, 2010.
19. Kempen, J.H., Altaweel, M.M., Holbrook, J.T., et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone actinide implant for intermediate, posterior, and panuveitis: The multicenter uveitis steroid treatment trial. Ophthalmology. 118:1916-1926, 2011.
20. Yeh, S., Cebulla, C.M., Witherspoon, S.R., et al. Management of fluocinolone implant dissociation during implant exchange. Arch. Ophthalmol. 127:1218-1221, 2009.
21. Nicholson, B.P., Singh, R.P., Sears, J.E., et al. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Am. J. Ophthalmol. 154:969-973, 2012.
22. Akduman, L., Cetin, E.N., Levy, J., et al. Spontaneous dissociation and dislocation of Retisert pellet. Ocul. Immunol. Inflamm. 21:87-89, 2013.
23. Rofagha, S., Prechanond, T., and Stewart, J.M. Late spontaneous dissociation of a fluocinolone actinide implant (Retisert). Ocul. Immunol. Inflamm. 21:62-63, 2013.
24. Chang, P.Y., Kresch, Z., Samson, C.M., and Gentile, R.C. Spontaneous dissociation of fluocinolone acetonide sustained release implant (Retisert) with dislocation into the anterior chamber. Ocul. Immunol. Inflamm. 11:1-4, 2014.
25. Itty, S., Callanan, D., Jones, R., et al. Spontaneous dislocation of fluocinolone acetonide implant pellets from their suture struts. Am. J. Ophthalmol. 159:868-876, 2015.
26. Pearson, P.A., Comstock, T.L., Ip, M., et al. Fluocinolone actinide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 118:1580-1587, 2011.
27. Jain, N., Stinnett, S.S., and Jaffe, G.J. Prospective study of a fluocinolone actinide implant for chronic macular edema from central retinal vein occlusion: Thirty-six-month results. Ophthalmology. 119:132-137, 2012.
28. Campochiaro, P.A., Brown, D.M., and Pearson, A. Sustained delivery fluocinolone actinide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 119:2125-2132, 2012.
29. Mansoor, S., Kuppermann, B.D., and Kenney, M.C. Intraocular sustained-release delivery systems for triamcinolone actinide. Pharm. Res. 26:770-784, 2009.
30. Kiss, S. Sustained-release corticosteroid delivery systems. Retina Today. 44-46, 2010.
31. Dugel, P.U., Eliott, D., Cantrill, H.L., et al. I-vation TM TA: 24-month clinical results of the phase I safety and preliminary efficacy study. In Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, FL, 2009.
32. Haller, J.A., Bandello, F., Belfort Jr., R., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 117:1134-1146, 2010.
33. Lowder, C., Belfort Jr., R., Lightman, S., et al. Ozurdex HURON study group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol. 129:545-553, 2011.
34. Boyer, D.S., Faber, D.J., Gupta, S.K., et al. Ozurdex Champlain Study Group: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 31:915-923, 2011.
35. Callanan, D., Gupta, S., Boyer, D., et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 120:1843-1851, 2013.
36. Gupta, A., Ram, J., Gupta, A., and Gupta, V. Intraoperative dexamethasone implant in uveitis patients with cataract undergoing phacoemulsification. Ocul. Immunol. Inflamm. 21:462-467, 2013.
37. Agarwal, A., Gupta, V., Ram, J., and Gupta, A. Dexamethasone intravitreal implant during phacoemulsification. Ophthalmology. 120:211, 211.e1-e5, 2013.
38. Guigou, S., Hajjar, C., Parrat, E., et al. Multicenter Ozurdex assessment for diabetic macular edema: MOZART study. J. Fr. Ophtalmol. 37:480-485, 2014
39. Gillies, M.C., Lim, L.L., Campain, A., et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology. 121:2473-2481, 2014.
40. Boyer, D.S.,Yoon, Y.H.,Belfort Jr., R., et al. theMEADstudy group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 121:1904-1914, 2014.
41. Bansal, P., Gupta, V., Gupta, A., Dogra, M.R., and Ram, J. Efficacy of Ozurdex implant in recalcitrant diabetic macular edema-a single-center experience. Int. Ophthalmol. 2015. DOI: 10.1007/s10792-015-0103-5. Epub Aug 2.
42. Bansal, P., Agarwal, A., Gupta, V., Singh, R., and Gupta, A. Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex in patients with uveitic cystoid macular edema. Indian J. Ophthalmol. 63:416-422, 2015.
43. Bansal, R., Bansal, P., Kulkarni, P., et al.Wandering Ozurdex implant. J. Ophthalmic Inflamm. Infect. 2:1-5, 2012.
44. Gao, H., Qiao, X., Cantor, L.B., and WuDunn, D. Upregulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch. Ophthalmol. 120:797-803, 2002.
45. Burke, J., and Schwartz, M. Preclinical evaluation of brimonidine. Surv. Ophthalmol. 41 Suppl 1:S9-S18, 1996.
46. Lai, R.K., Chun, T., Hasson, D., et al. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis. Neurosci. 19:175-185, 2002.
47. Wolde, M.E., Ruiz, G., Wijono, M., and Wheeler, L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 42:2849-2855, 2001.
48. Wheeler, L., Wolde, M.E., and Lai, R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 48 Suppl 1: S47-S51, 2003.
49. Olsen, T.W., Feng, X., Wabner, K., et al. Cannulation of the suprachoroidal space: A novel drug delivery methodology to the posterior segment. Am. J. Ophthalmol. 142:777-787, 2006.
50. Olsen, T.W., Feng, X., Wabner, K., et al. Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. Invest. Ophthalmol. Vis. Sci. 52:4749-4756, 2011.
51. Patel, S.R., Lin, A.S., Edelhauser, H.F., and Prausnitz, M.R. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res. 28:166-176, 2011.
52. Augustin, C., Augustin, A., Tetz, M., and Rizzo, S. Suprachoroidal drug delivery-a new approach for the treatment of severe macular diseases. Eur. Ophthalmic Rev. 6:25-27, 2012.
53. Tetz, M., Rizzo, S., and Augustin, A.J. Safety of submacular suprachoroidal drug administration via a microcatheter: Retrospective analysis of European treatment results. Ophthalmologica. 227:183-189, 2012.
54. Rizzo, S., Ebert, F.G., Bartolo, E.D., et al. Suprachoroidal drug infusion for the treatment of severe subfoveal hard exudates. Retina. 32:776-784, 2012.
55. Pearce, W., Hsu, J., and Yeh, S. Advances in drug delivery to the posterior segment. Curr. Opin. Ophthalmol. 26:233-239, 2015.
56. Myles, M.E., Neumann, D.M., and Hill, J.M. Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. 57:2063-2079, 2005.
57. Singh, R.P., Mathews, M.E., Kaufman, M., and Riga, A. Transcleral delivery of triamcinolone actinide and ranibizumab to retinal tissues using macroesis. Br. J. Ophthalmol. 94:170-173, 2010.
58. Higuchi, W., Tuitupou, A.L.,Kochamblll, R.P., et al. Delivery of sustained release formulation of triamcinolone actinide to the rabbit eye using the VisulexTM ocular iontophoresis device. Invest. Ophthalmol. Vis. Sci. 47:5108, 2006.
59. Parkinson, T.M., Ferguson, E., Febbraro, S., et al. Tolerance of ocular iontophoresis in healthy volunteers. J. Ocul. Pharmacol. Ther. 19:145-151, 2003.
60. Halha, M., Renard, G., Courtois, Y., BenEzra, D., and Behar-Cohen, F. Iontophoresis: From the lab to the bed side. Exp. Eye Res. 78:751-757, 2004.
61. Zhang, K., Hopkins, J.J., Heier, J.S., et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 108:6241-6245, 2001.
62. Birch, D.G., Weleber, R.G., Duncan, J.L., et al.; Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Groups. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am. J. Ophthalmol. 156:283-292, 2013.
63. Guerrero-Naranjo, J.L., et al. Safety of implantation of the NT-503 device in patients with choroidal neovascularization secondary to age-related macular degeneration. Abstract Presented at Association for Research in Vision and Ophthalmology, 2013, Seattle, WA.
64. Yeh, S., Albini, T.A., and Moshfeghi, A.A. A peek down the pipeline: Emerging drug-delivery options for retinal diseases. Adv. Ocul. Care. 32-37, 2015.
65. Ebrahim, S., Peyman, G.A., and Lee, P.J. Applications of liposomes in ophthalmology. Surv. Ophthalmol. 50:167-182, 2005.
66. Honda, M., Asai, T., Oku, N., et al. Liposomes and nanotechnology in drug development: Focus on ocular targets. Int. J. Nanomedicine. 8:495-504, 2013.
67. Saini, N., and Kumar, D. An Insight To Ophthalmic Drug Delivery System. Int. J. Pharm. Stud. Res. 3:9-13, 2012.
68. Abrishami, M., Zarei-Ghanavati, S., Soroush, D., et al. Preparation, characterization and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina. 29:699-703, 2009.
69. Tiwari, A., and Shukla, R.K. Novel ocular drug delivery systems: An overview. J. Chem. Pharm. Res. 2:348-355, 2010.
70. Carrasquillo, K.G. et al. (2003) Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic) acid microspheres. Invest. Ophthalmol. Vis. Sci. 2003;44: 290-299.
71. Saishin, Y., Silva, R.L., Saishin, Y., et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. 44:4989-4993, 2003.
72. Lim, J.I., Hung, D., Fung, A.E., Wieland, M., and Wong, V. One year results of a Phase 1 study evaluating the safety and evidence of efficacy of a single intravitreal injection of the VerisomeTM liquid drug delivery system for sustained release of low-dose triamcinolone (IBI-20089) in eyes with cystoid macular edema. In Proceedings of ARVO 2010 Annual Meeting, Fort Lauderdale, FL, 2010; E-Abstract 6396.
73. ClinicalTrials.gov IBI. 20089+Lucentis combo intravitreal injections for treatment of neovascular age-related macular degeneration (AMD) (Icon Combo). Available at http://clinicaltrials.gov/ct2/show/NCT01175395?term=IBI20089 &rank=1 (accessed on September 10, 2015).
74. Kuno, N., and Fujii, S. Recent advances in ocular drug delivery systems. Polymers. 3:193-221, 2011.
75. Mainardes, R.M., Urban, M.C., Cinto, P.O., et al. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets. 6:363-371, 2005.
76. Shah, S.S., Denham, L.V., Elison, J.R., et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev. Ophthalmol. 5:75-93, 2010.
77. Tolentino, M.J., Dennrick, A., Elizabeth John, E., et al. Drugs in Phase II clinical trials for the treatment of agerelated macular degeneration. Expert Opin. Investig. Drugs. 24:183-199, 2015.
78. Derwent, J.K., and Mieler, W.F. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans. Am. Ophthalmol. Soc. 206-214, 200